Immunodeficiency News and Research

RSS

Immunodeficiency (or immune deficiency) is a state in which the immune system's ability to fight infectious disease is compromised or entirely absent.

Comparative study on African monkeys may provide novel targets for AIDS therapy

Two studies published this month in the Journal of Clinical Investigation provide a significant advance in understanding how some species of monkeys such as sooty mangabeys and African green monkeys avoid AIDS when infected with SIV, the simian equivalent of HIV.

5 Dec 2009

Global HIV reporting and monitoring system provides good indication of overall progress towards HIV goal

3 Dec 2009

FDA approves additional intended use of Roche's cobas TaqScreen MPX Test

Roche announced today that the United States Food & Drug Administration (FDA) approved an additional intended use for its licensed nucleic acid test, to screen source plasma in pools comprised of up to 96 individual donations. The test, called the cobas® TaqScreen MPX Test for use on the cobas s 201 system, is a qualitative, in-vitro test for the simultaneous, direct detection of the human immunodeficiency virus (HIV-1 Group M RNA, HIV-1 Group O RNA , HIV-2 RNA), hepatitis C virus RNA and hepatitis B virus DNA in human plasma.

From Roche Sequencing and Life Science 2 Dec 2009

Department of Health reminds Pennsylvanians to be tested regularly for HIV

In recognition of World AIDS Day on Dec. 1, Department of Health Secretary Everette James today reminded Pennsylvanians to be tested regularly for HIV - the virus that causes AIDS.

1 Dec 2009

Avioq receives premarket approval from FDA for Avioq HIV-1 Microelisa System

Avioq, Inc. announced it has received premarket approval from the U.S. Food and Drug Administration (FDA) for the Avioq HIV-1 Microelisa System.

1 Dec 2009

Reductionist model provides new insights on HIV infection

A major obstacle to HIV research is the virus's exquisite specialisation for its human host - meaning that scientists' traditional tools, like the humble lab mouse, can deliver only limited information. Now, a team of researchers writing in BioMed Central's open access Journal of Biology have made an ingenious assault on this problem by creating a mouse that has key features of HIV infection without being infected with HIV.

1 Dec 2009

WHITIA launches digital medical X-ray device for screening infectious diseases in developing countries

The World Health Imaging, Telemedicine and Informatics Alliance (WHITIA) today unveiled Remi-d, a new product concept that is intended to provide remote-operated X-ray capabilities for use in screening across areas of the developing world experiencing the Human Immunodeficiency Virus (HIV) and Tuberculosis (TB) co-epidemic, high incidences of Black Lung disease, or outbreaks of other infectious respiratory diseases.

30 Nov 2009

Tibotec Therapeutics' INTELENCE granted FDA traditional approval

The FDA granted traditional approval for INTELENCE® (etravirine) tablets, a non-nucleoside reverse transcriptase inhibitor (NNRTI). INTELENCE is the only NNRTI specifically indicated for use in treatment-experienced adults who are experiencing virologic failure with HIV-1 strains resistant to an NNRTI and other antiretroviral (ARV) agents.

25 Nov 2009

Pediatric immunologist receives prestigious annual award from American Philosophical Society

A pediatric immunologist at The Children's Hospital of Philadelphia has received a prestigious annual award from the American Philosophical Society, an organization founded in 1743 by Benjamin Franklin. Jordan S. Orange, M.D., Ph.D., received the Society's Judson Daland Prize on Nov. 13 for his contributions to research and treatment of inherited immune deficiency diseases.

20 Nov 2009

UNGASS monitoring system provides the overall progress in the global response to HIV

Although much work remains to be done, a United Nations global reporting system on HIV/AIDS has already yielded an "unequaled wealth of data" on progress toward meeting UN targets for responding to the global HIV epidemic. An update on the development of the UN General Assembly Special Session on HIV/AIDS (UNGASS) global reporting system appears in a special supplement to JAIDS: Journal of Acquired Immune Deficiency Syndromes.

19 Nov 2009

Request for pre-IND meeting to discuss IND application for therapeutic vaccine granted by FDA

GeoVax Labs, Inc. (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that the U.S. Food and Drug Administration (FDA) has granted its request for a pre-IND meeting to discuss the proposed Investigational New Drug (IND) application for GeoVax's therapeutic vaccine as a treatment for individuals already infected with HIV.

18 Nov 2009

Scientists describe how HIV assemble at the membrane of infected cells and are released to attack healthy cells

Although recent advances have raised hopes that a protective vaccine can be developed, acquired immunodeficiency syndrome (AIDS) remains a major public health problem. Much has been learned about HIV-1, the virus that causes the disease.

13 Nov 2009

New findings on human genome may be useful for developing specific AIDS drugs

The AIDS virus inserts its genetic material into the genome of the infected cell. Scientists of the German Cancer Research Center have now shown for the first time that the virus almost entirely spares particular sites in the human genetic material in this process. This finding may be useful for developing new, specific AIDS drugs.

13 Nov 2009

Tips for preventing cancer

The risk of cancer can be dramatically reduced through everyday choices about diet, exercise and tobacco use, according to a Special Report on Cancer Prevention in the November issue of Mayo Clinic Women's HealthSource.

12 Nov 2009

NIH awards $6.8 million subcontract to Kineta to develop vaccine immune boosters

Kineta, Inc. announced today it has been awarded a $6.8 million subcontract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop novel vaccine adjuvants (agents that help boost the immune system). The Kineta subcontract is part of a larger $13 million award to the University of Washington.

10 Nov 2009

NIH awards UAB School of Public Health $11.5M to research new methods of identifying youth with HIV

The University of Alabama at Birmingham (UAB) School of Public Health has been awarded a total of $11.5 million from the National Institutes of Health to explore new ways to identify adolescents and young adults infected with human immunodeficiency virus (HIV) and link them to medical care.

7 Nov 2009

GeoVax Labs announces financial results and operational update for the third quarter of 2009

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2009 financial results and provided an operational update.

6 Nov 2009

Eggs sensitivity and flu shot: Doctors' dilemma

"My three year old had a skin breakout we think was due to eggs - is it safe to do a flu shot?" It's a question being asked to every doctor who takes care of kids during flu season. "On the one hand we are concerned about the devastating effects of the new strain of flu, and on the other we aren't sure if a history of eggs sensitivity is enough to hold the shot or spray," said Bobby Q. Lanier, M.D., clinical professor of pediatrics at the University of North Texas HSC in Fort Worth, Texas, and executive medical director of the American College of Allergy, Asthma and Immunology (ACAAI).

6 Nov 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.

5 Nov 2009

Immunotherapy, a new therapeutic area to destroy tumor cells

Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).

31 Oct 2009

Immunodeficiency News and Research

Further Reading

Comparative study on African monkeys may provide novel targets for AIDS therapy

Global HIV reporting and monitoring system provides good indication of overall progress towards HIV goal

FDA approves additional intended use of Roche's cobas TaqScreen MPX Test

Department of Health reminds Pennsylvanians to be tested regularly for HIV

Avioq receives premarket approval from FDA for Avioq HIV-1 Microelisa System

Reductionist model provides new insights on HIV infection

WHITIA launches digital medical X-ray device for screening infectious diseases in developing countries

Tibotec Therapeutics' INTELENCE granted FDA traditional approval

Pediatric immunologist receives prestigious annual award from American Philosophical Society

UNGASS monitoring system provides the overall progress in the global response to HIV

Request for pre-IND meeting to discuss IND application for therapeutic vaccine granted by FDA

Scientists describe how HIV assemble at the membrane of infected cells and are released to attack healthy cells

New findings on human genome may be useful for developing specific AIDS drugs

Tips for preventing cancer

NIH awards $6.8 million subcontract to Kineta to develop vaccine immune boosters

NIH awards UAB School of Public Health $11.5M to research new methods of identifying youth with HIV

GeoVax Labs announces financial results and operational update for the third quarter of 2009

Eggs sensitivity and flu shot: Doctors' dilemma

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Immunotherapy, a new therapeutic area to destroy tumor cells

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News